Trial Profile
A Phase 2 Study of Poziotinib in Patients With Non-Small Cell Lung Cancer (NSCLC), Locally Advanced or Metastatic, With EGFR or HER2 Exon 20 Insertion Mutation (ZENITH20)
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 11 Mar 2024
Price :
$35
*
At a glance
- Drugs Poziotinib (Primary) ; Loperamide
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Registrational; Therapeutic Use
- Acronyms POZITIVE20-1; ZENITH20; ZENITH20-1; ZENITH20-2; ZENITH20-4; ZENITH20-5
- Sponsors Spectrum Pharmaceuticals
- 24 Jan 2024 Status changed from active, no longer recruiting to discontinued.
- 27 Oct 2023 This trial has been completed in Belgium (global end date: 2023-04-03), according to European Clinical Trials Database.
- 12 Sep 2023 Results assessing efficacy and safety results of poziotinib in NSCLC patients harboring HER2 exon 20 mutations who previously received at least two lines of systemic therapies, including a platinum-based regimen, presented at the 24th World Conference on Lung Cancer.